Lupin partners with Boehringer lngelheim

04 Sep 2019

Lupin and Boehringer lngelheim have entered into licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin's lead MEK inhibitor compound in combination with one of Boehringer lngelheim's innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Related Lupin Ltd. Links:

Lupin Share Price

869.30 8.55 (0.99%) Jul 13, 18:01
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 499.65
Dr. Reddys Lab 3898.60
Lupin 869.30
Piramal Enterprises 1432.20
Cadila Healthcare 358.20
View more..
Sensex vs Lupin
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback